VBI Vaccines (NASDAQ:VBIV – Get Free Report) and Xilio Therapeutics (NASDAQ:XLO – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
Risk and Volatility
VBI Vaccines has a beta of 2, indicating that its stock price is 100% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.07, indicating that its stock price is 107% less volatile than the S&P 500.
Earnings & Valuation
This table compares VBI Vaccines and Xilio Therapeutics’ revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
VBI Vaccines | $9.41 million | 1.97 | -$92.84 million | N/A | N/A |
Xilio Therapeutics | N/A | N/A | -$76.40 million | ($2.57) | -0.35 |
Profitability
This table compares VBI Vaccines and Xilio Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
VBI Vaccines | -881.79% | -525.42% | -45.87% |
Xilio Therapeutics | N/A | -153.48% | -89.26% |
Insider and Institutional Ownership
12.3% of VBI Vaccines shares are owned by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are owned by institutional investors. 10.4% of VBI Vaccines shares are owned by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for VBI Vaccines and Xilio Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
VBI Vaccines | 0 | 0 | 0 | 0 | N/A |
Xilio Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Summary
Xilio Therapeutics beats VBI Vaccines on 5 of the 9 factors compared between the two stocks.
About VBI Vaccines
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
About Xilio Therapeutics
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.